The present invention relates to a compound of dihydrophaseic acid 3-O-beta-D-glucopyranoside for the prevention and treatment of osteoporosis. It was found that the D3G isolated from the lycium root bark extract induces the activity of osteoblast differentiation while promoting the proliferation of pre-osteoblast, and promotes the bone remodeling by promoting the differentiation of both osteoblast and osteoclast when mixing and culturing pre-osteoblast which is the precursor of osteoblast, and monocyte which is the precursor of osteoclast. Therefore, the D3G of the present invention is expected to be useful as a pharmacological agent or functional food effective for the prevention and treatment of osteoporosis which is a disease caused by the abnormal balance of bone remodeling,

The present invention relates to a compound of dihydrophaseic acid 3-O-beta-D-glucopyranoside for the prevention and treatment of osteoporosis. It was found that the D3G isolated from the lycium root bark extract induces the activity of osteoblast differentiation while promoting the proliferation of pre-osteoblast, and promotes the bone remodeling by promoting the differentiation of both osteoblast and osteoclast when mixing and culturing pre-osteoblast which is the precursor of osteoblast, and monocyte which is the precursor of osteoclast. Therefore, the D3G of the present invention is expected to be useful as a pharmacological agent or functional food effective for the prevention and treatment of osteoporosis which is a disease caused by the abnormal balance of bone remodeling,

The present invention comprises a method for selecting lactic acid bacterial strains effective for preventing bone loss in humans and strains that have been selected according to the presented method. The selection method is based on the strain's capability of reestablishing an altered microbial community to normal and/or harboring at least one of four specific SNPs.

The present invention comprises a method for selecting lactic acid bacterial strains effective for preventing bone loss in humans and strains that have been selected according to the presented method. The selection method is based on the strain's capability of reestablishing an altered microbial community to normal and/or harboring at least one of four specific SNPs.

The present invention is a nutraceutical formulation, intended for oral administration, comprising co-administered if not co-formulated melatonin together with at least one of strontium, Vitamin D, and Vitamin K or their analogues. The nutraceutical combination or formulation is designed to be taken by mouth within about two hours prior to bedtime, and in fact should not be taken at any other time. The combination therapy gives new and unexpectedly improved results compared to the administration of melatonin alone.

The present invention is a nutraceutical formulation, intended for oral administration, comprising co-administered if not co-formulated melatonin together with at least one of strontium, Vitamin D, and Vitamin K or their analogues. The nutraceutical combination or formulation is designed to be taken by mouth within about two hours prior to bedtime, and in fact should not be taken at any other time. The combination therapy gives new and unexpectedly improved results compared to the administration of melatonin alone.

An object of the present invention is to provide a safety sensation-improving agent that can improve dulled peripheral sensations through daily ingestion or application to the skin. Another object of the present invention is to provide a sensation-improving food, beverage, feed, or cosmetics that can improve dulled peripheral sensations through oral ingestion or application to the skin. A sensation-improving agent containing a milk-derived protein and/or a hydrolysate therefrom as an active ingredient is provided. The milk-derived protein and/or the hydrolysate therefrom can be orally ingested or applied direct to the skin to improve dulled sensations, particularly peripheral sensations, and be formed into a sensation-improving food, beverage, feed, or cosmetics.

An object of the present invention is to provide a safety sensation-improving agent that can improve dulled peripheral sensations through daily ingestion or application to the skin. Another object of the present invention is to provide a sensation-improving food, beverage, feed, or cosmetics that can improve dulled peripheral sensations through oral ingestion or application to the skin. A sensation-improving agent containing a milk-derived protein and/or a hydrolysate therefrom as an active ingredient is provided. The milk-derived protein and/or the hydrolysate therefrom can be orally ingested or applied direct to the skin to improve dulled sensations, particularly peripheral sensations, and be formed into a sensation-improving food, beverage, feed, or cosmetics.

A pet food composition specifically formulated for a small dog can include a combination of specific amino acids and probiotics to maintain or increase absorption of amino acids. Methods of increasing absorption of amino acids are also provided.

A pet food composition specifically formulated for a small dog can include a combination of specific amino acids and probiotics to maintain or increase absorption of amino acids. Methods of increasing absorption of amino acids are also provided.